ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0269

Systemic Lupus Erythematosus with Libman-Sacks Endocarditis Increases Inpatient Mortality

Ehizogie Edigin1, Precious Eseaton2, Pius Ojemolon3 and Augustine Manadan4, 1John H Stroger Jr. Hospital of Cook County, Chicago, IL, 2University of Benin Teaching Hospital, Benin, 3St. George's University, St. George's, Grenada, 4Cook County Hospital/Rush University Medical center, Chicago, IL

Meeting: ACR Convergence 2020

Keywords: Administrative Data, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster I: Clinical Manifestations

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Libman-Sacks endocarditis characterized by thrombotic and/or non-infective sterile inflammatory vegetations are common in Systemic Lupus Erythematosus (SLE) and associated with increased morbidity. These vegetations can be complicated with superimposed infective endocarditis, embolic cerebrovascular disease, severe valvular regurgitation, and need for high-risk valve surgery. The study aims to compare the outcomes of SLE hospitalizations with and without Libman-Sacks endocarditis. The primary outcome was inpatient mortality, while secondary outcomes were hospital length of stay (LOS) and total hospital charges.

Methods: Data were abstracted from the National Inpatient Sample (NIS) 2016 and 2017 Database. This database is the largest collection of inpatient admission data in the USA. It is a nationally representative sample of 20% of hospitalizations from approximately 1,000 hospitals.  The numbers in the databases are weighted to optimize national estimates. The NIS was searched for SLE hospitalizations with Libman-Sacks endocarditis (“M32.11”) and SLE without endocarditis (remaining M32 ICD-10 codes) as principal or secondary diagnosis. SLE hospitalizations for adult patients (age≥ 18 years) from the above groups were identified. Multivariate logistic and linear regression analysis was used to adjust for confounders for the primary and secondary outcomes respectively. Confounders adjusted for include age, sex, race, median income expected for zip code, Charleston comorbidity index, insurance status, and hospital location/region/teaching status and bed size. STATA software was used to analyze the data.

Results: There were combined 71 million discharges included in the 2016 and 2017 NIS database. 355,740 hospitalizations were for adult patients, who had either a principal or secondary ICD-10 code for SLE. 680 (0.19%) and 355,060 (99.81%) of these hospitalizations were for SLE with and without Libman-Sacks endocarditis respectively. The mean age for SLE with Libman-Sacks endocarditis was 43 vs 52 years without endocarditis (P< 0.001). 7,060 adult SLE hospitalizations (2%) resulted in inpatient mortality. 45 (6.6%) deaths occurred in SLE with Libman-Sacks endocarditis vs 7,015 (2%) without endocarditis (P=0.0001). The adjusted odds ratio (AOR) for inpatient mortality for SLE with Libman-Sacks endocarditis compared to those without endocarditis was 3.64 (95% CI 1.63-8.12, P=0.002). SLE with Libman-Sacks endocarditis hospitalizations had an increase in mean adjusted LOS of 5.22 days (95% CI 1.54-8.90, P=0.005) compared to SLE without endocarditis. Hospitalizations for SLE with Libman-Sacks endocarditis had an increase in mean adjusted total charges by $53,507 compared to SLE without endocarditis (95% CI 10,611-96,404, P=0.015).

Conclusion: Hospitalizations for SLE with Libman-Sacks endocarditis have more than 3 times the risk of in-hospital death compared to those without endocarditis. Hospitalizations for SLE with Libman-Sacks endocarditis have statistically and clinically significant increase in LOS and mean total hospital charges compared to those without endocarditis.


Disclosure: E. Edigin, None; P. Eseaton, None; P. Ojemolon, None; A. Manadan, None.

To cite this abstract in AMA style:

Edigin E, Eseaton P, Ojemolon P, Manadan A. Systemic Lupus Erythematosus with Libman-Sacks Endocarditis Increases Inpatient Mortality [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/systemic-lupus-erythematosus-with-libman-sacks-endocarditis-increases-inpatient-mortality/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/systemic-lupus-erythematosus-with-libman-sacks-endocarditis-increases-inpatient-mortality/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology